sb 203580 has been researched along with pristane in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (pristane) | Trials (pristane) | Recent Studies (post-2010) (pristane) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 506 | 0 | 195 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, M; Holmdahl, R; Jiang, C; Lu, S; Ma, J; Meng, L; Sun, J; Wu, X; Xu, J; Zhu, W | 1 |
1 other study(ies) available for sb 203580 and pristane
| Article | Year |
|---|---|
Pristane primed rat T cells enhance TLR3 expression of fibroblast-like synoviocytes via TNF-α initiated p38 MAPK and NF-κB pathways.
Topics: Animals; Arthritis, Experimental; CD4-Positive T-Lymphocytes; Cell Line; Culture Media, Conditioned; Enzyme Inhibitors; Humans; Imidazoles; Immunosuppressive Agents; Interferon-gamma; Interleukin-17; Interleukin-6; Matrix Metalloproteinase 13; Matrix Metalloproteinase 3; NF-kappa B; Nitriles; p38 Mitogen-Activated Protein Kinases; Pyridines; Rats; RNA, Messenger; Sulfones; Synovial Membrane; Terpenes; Toll-Like Receptor 3; Tumor Necrosis Factor-alpha; Up-Regulation | 2015 |